Cargando…

Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations

Anti-nuclear antibody (ANA) assay is a screening test used for almost all autoimmune rheumatic diseases, and in a number of these cases, it is a diagnostic/classification parameter. In addition, ANA is also a useful test for additional autoimmune disorders. The indirect immunofluorescence technique...

Descripción completa

Detalles Bibliográficos
Autores principales: Meroni, Pier Luigi, Bizzaro, Nicola, Cavazzana, Ilaria, Borghi, Maria Orietta, Tincani, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939809/
https://www.ncbi.nlm.nih.gov/pubmed/24589329
http://dx.doi.org/10.1186/1741-7015-12-38
_version_ 1782305742407073792
author Meroni, Pier Luigi
Bizzaro, Nicola
Cavazzana, Ilaria
Borghi, Maria Orietta
Tincani, Angela
author_facet Meroni, Pier Luigi
Bizzaro, Nicola
Cavazzana, Ilaria
Borghi, Maria Orietta
Tincani, Angela
author_sort Meroni, Pier Luigi
collection PubMed
description Anti-nuclear antibody (ANA) assay is a screening test used for almost all autoimmune rheumatic diseases, and in a number of these cases, it is a diagnostic/classification parameter. In addition, ANA is also a useful test for additional autoimmune disorders. The indirect immunofluorescence technique on monolayers of cultured epithelial cells is the current recommended method because it has higher sensitivity than solid phase assays. However, the technique is time-consuming and requires skilled operators. Automated ANA reading systems have recently been developed, which offer the advantage of faster and much easier performance as well as better harmonization in the interpretation of the results. Preliminary validation studies of these systems have given promising results in terms of analytical specificity and reproducibility. However, these techniques require further validation in clinical studies and need improvement in their recognition of mixed or less common staining patterns.
format Online
Article
Text
id pubmed-3939809
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39398092014-03-04 Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations Meroni, Pier Luigi Bizzaro, Nicola Cavazzana, Ilaria Borghi, Maria Orietta Tincani, Angela BMC Med Commentary Anti-nuclear antibody (ANA) assay is a screening test used for almost all autoimmune rheumatic diseases, and in a number of these cases, it is a diagnostic/classification parameter. In addition, ANA is also a useful test for additional autoimmune disorders. The indirect immunofluorescence technique on monolayers of cultured epithelial cells is the current recommended method because it has higher sensitivity than solid phase assays. However, the technique is time-consuming and requires skilled operators. Automated ANA reading systems have recently been developed, which offer the advantage of faster and much easier performance as well as better harmonization in the interpretation of the results. Preliminary validation studies of these systems have given promising results in terms of analytical specificity and reproducibility. However, these techniques require further validation in clinical studies and need improvement in their recognition of mixed or less common staining patterns. BioMed Central 2014-03-03 /pmc/articles/PMC3939809/ /pubmed/24589329 http://dx.doi.org/10.1186/1741-7015-12-38 Text en Copyright © 2014 Meroni et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Meroni, Pier Luigi
Bizzaro, Nicola
Cavazzana, Ilaria
Borghi, Maria Orietta
Tincani, Angela
Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
title Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
title_full Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
title_fullStr Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
title_full_unstemmed Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
title_short Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
title_sort automated tests of ana immunofluorescence as throughput autoantibody detection technology: strengths and limitations
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939809/
https://www.ncbi.nlm.nih.gov/pubmed/24589329
http://dx.doi.org/10.1186/1741-7015-12-38
work_keys_str_mv AT meronipierluigi automatedtestsofanaimmunofluorescenceasthroughputautoantibodydetectiontechnologystrengthsandlimitations
AT bizzaronicola automatedtestsofanaimmunofluorescenceasthroughputautoantibodydetectiontechnologystrengthsandlimitations
AT cavazzanailaria automatedtestsofanaimmunofluorescenceasthroughputautoantibodydetectiontechnologystrengthsandlimitations
AT borghimariaorietta automatedtestsofanaimmunofluorescenceasthroughputautoantibodydetectiontechnologystrengthsandlimitations
AT tincaniangela automatedtestsofanaimmunofluorescenceasthroughputautoantibodydetectiontechnologystrengthsandlimitations